In the heat of the most ferocious battle over drug prices in years, pharmaceutical companies are showering U.S. senators with campaign cash as sweeping legislation heads toward the floor.
America provides the world’s highest-priced care with the lowest life expectancy of developed countries, with half of all bankruptcies related to healthcare costs, while one in seven Medicare beneficiaries is harmed while hospitalized, Dr. Douglas Walta told students last week.
The Pharmaceutical Researchers and Manufacturers of America appear likely to succeed at watering down a bill designed to give the Oregon Health Authority the chance to screen new blockbuster drugs before they are given to Medicaid patients.
The Pharmaceutical Research and Manufacturers of America is asking for a midstream change to legislation that allows the Oregon Health Authority to deny payment for high-priced blockbuster drugs for six months after they’ve been approved by the U.S. Food and Drug Administration.
Working in collaboration with Oregon’s university medical schools, hospitals and clinical research centers, biopharmaceutical companies are conducting or have conducted since 1999 more than 2,300 clinical trials of new medicines in the state, a released today shows.